Tetramethylpyrazine alleviates ventricular remodeling after myocardial infarction by regulating Sirt1/p300/Yy1/sST2 signaling axis
Open Access
- 4 December 2025
- journal article
- Published by Elsevier in Phytomedicine
- Vol. 150, 157662
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82274135)
- Tianjin Municipal Natural Science Foundation (23JCYBJC00830)
This publication has 39 references indexed in Scilit:
- Tetramethylpyrazine protects against myocardial ischemia/reperfusion injury via regulating Myl2-mediated NLRP3 signaling pathway inhibitionCellular Signalling, 2025
- Protective effects of tetramethylpyrazine on myocardial ischemia/reperfusion injury involve NLRP3 inflammasome suppression by autophagy activationBiochemical Pharmacology, 2024
- Lifestyle effects on aging and CVD: A spotlight on the nutrient-sensing networkAgeing Research Reviews, 2023
- Tetramethylpyrazine and Astragaloside IV have synergistic effects against spinal cord injury-induced neuropathic pain via the OIP5-AS1/miR-34a/Sirt1/NF-κB axisInternational Immunopharmacology, 2022
- Long-term Outcomes in Patients With Severely Reduced Left Ventricular Ejection Fraction Undergoing Percutaneous Coronary Intervention vs Coronary Artery Bypass GraftingJAMA Cardiology, 2020
- Role of Sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogrammingAgeing Research Reviews, 2018
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2017
- Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015JACC, 2017
- ST2 in Stable and Unstable Ischemic Heart DiseasesThe American Journal of Cardiology, 2015
- Serum Soluble ST2JACC, 2010